Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors
Orphazyme investors have until September 7, 2021 to file a lead plaintiff motion.
- Orphazyme investors have until September 7, 2021 to file a lead plaintiff motion.
- You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
- In September 2020, Orphazyme completed its IPO, selling approximately 4 million ADSs at $11.00 per share.
- The same month, the Companys New Drug Application (NDA) for arimoclomol for NPC was accepted by the U.S. Food and Drug Administration (FDA).